[
    "ls may therefore be used. </p> Once a crystal of the present invention is grown, X-ray diffraction data can be collected. Crystals can be characterized by using X-rays produced in a conventional source (such as a sealed tube or a rotating anode) or using a synchrotron source. Methods of characterization include, but are not limited to, precision photography, oscillation photography and diffractometer data collection. Se-Met multiwavelength anamalous dispersion data. </p> Once the three-dimensional structure of a protein-ligand complex formed between a p21 derived peptide of the present invention and cyclin A is determined, a candidate compound may be examined through the use of computer modeling using a docking program such as GRAM, DOCK or AUTODOCK [Dunbrack et al., 1997, Folding &amp; Design 2:R27-42]. This procedure can include computer fitting of candidate compounds to the ligand binding site to ascertain how well the shape and the chemical structure of the candidate compound will complement the binding site. [Bugg et al., Scientific American, December:92-98 (1993); West et al;l TIPS, 16:67-74 (1995)]. Computer programs can also be employed to estimate the attraction, repulsion and steric hindrance of the two binding partners (i.e. the ligand-binding site and the candidate compound). Generally the tighter the fit, the lower the steric hindrances, and the greater the attractive forces, the more potent the potential drug since these properties are consistent with a tighter binding constant. Furthermore, the more specificity in the design of a potential drug the more likely that the drug will not interact as well with other proteins. This will minimize potential side-effects due to unwanted interactions with other proteins. </p> Initially candidate compounds can be selected for their structural similarity to a p21 derived peptide of the present invention such as HAKRRLIF, the four C-terminal amino acids thereof RLX<sub>5</sub>F or RLFX<sub>5</sub>; or variants or a region thereof. The structural analog can then be systematically modified by computer modeling programs or by inspection until one or more promising candidate compounds are identified. A candidate compound could be obtained by initially screening a random peptide library produced by recombinant bacteriophage for example [Scott and Smith, Science, 249:386-390 (1990); Cwirla et al., Proc. Natl. Acad. Sci., 87:6378-6382 (1990); Devlin et al., Science, 249:404-406 (1990)]. A peptide selected in this manner would then be systematically modified by computer modeling programs as described above, and then treated analogously to a structural analog as described below. </p> Once a candidate compound is identified it can be either selected from a library of chemicals as are commercially available or alternatively the candidate compound or antagonist may be synthesized de novo. As mentioned above, the de novo synthesis of one or even a relatively small group of specific compounds is reasonable in the art of drug design. The candidate compound can be placed into a standard binding assay with cyclin A together with a peptide of the present invention and its relative activity assessed. </p> In such an assay, cyclin A may be attached to a solid support. Methods for placing such a binding domain on the solid support are well known in the art and include such things as linking biotin to the ligand binding domain and linking avidin to the solid support. The solid support can be washed to remove unreacted species. A solution of a labeled candidate compound alone or together with a peptide of the present invention can be contacted with the solid support. The solid support is washed again to remove the candidate compound/peptide not bound to the support. The amount of labeled candidate compound remaining with the solid support and thereby bound to the ligand binding domain may be determined. Alternatively, or in addition, the dissociation constant between the labeled candidate compound and cyclin A can be determined. Alternatively, if a peptide of the present invention is used, it may be labeled and the decrease in bound labeled peptide used an indication of the relative activity of the candidate compound. Suitable labels are exemplified in our WO00/50896 (the contents of which are hereby incorporated by reference) which describes suitable fluorescent labels for use in fluorescent polarisation assays for protein/protein and protein/non-protein binding reactions. Such assay techniques are of use in the assays and methods of the present invention. </p> When suitable candidate compounds are identified, a supplemental crystal may be grown comprising a protein-candidate complex formed between cyclin A and the potential drug. Preferably the crystal effectively diffracts X-rays for the determination of the atomic coordinates of the protein-candidate complex to a resolution of greater than 5.0 Angstroms, more preferably greater than 3.0 Angstroms, and even more preferably greater than 2.0 Angstroms. The three-dimensional structure of the supplemental crystal may be determined by Molecular Replacement Analysis. Molecular replacement involves using a known three-dimensional structure as a search model to determine the structure of a closely related molecule or protein-candidate complex in a new crystal form. The measured X-ray diffraction properties of the new crystal are compared with the search model stru",
    "ns were aliquoted and stored at \u221270\u00b0 C. </p> GST-Rb\u2014An E coli expression construct containing the hyperphosphorylation domain of pRb (amino acids 773-924) was purified on a Glutathione-Sepharose column according to the manufacturers instructions (Pharmacia). For the 96-well format \u201cin vitro\u201d kinase assay GST-Rb was used immobilized on Glutathione-Sepharose beads. </p>Example 3 Enzyme Assays  CDK4/Cyclin D1, CDK2/Cyclin E, CDIK1/Cyclin B Kinase Assays Phosphorylation of GST-Rb </p> GST-Rb phosphorylation, induced by CDK4/Cyclin D1, CDK2/Cyclin E or CDK1/Cyclin B was determined by incorporation of radio-labeled phosphate in GST-Rb(772-928) using radiolabelled ATP in 96-well format in vitro kinase assay. The phosphorylation reaction mixture (total volume 40 \u03bcl) consisted of 50 mM HEPES pH 7.4, 20 mM MgCl2, 5 mM EGTA, 2 mM DTT, 20 mM ,\u03b2-glycerophosphate, 2 mM NaF, 1 mM Na3VO4, Protease Inhibitors Cocktail (Sigma, see above), BSA 0.5 mg/ml, 1 \u03bcg purified enzyme complex, 10 \u03bcl of GST-Rb-Sepharose beads, 100 \u03bcM ATP, 0.2 \u03bcCi <sup>32</sup>P-ATP. The reaction was carried out for 30 min at 30\u00b0 C. at constant shaking. At the end of this period 100 \u03bcl of 50 mM HEPES, pH 7.4 and 1 mM ATP were added to each well and the total volume was transferred onto GFC filtered plate. The plate was washed 5 times with 200 \u03bcl of 50 mM HEPES, pH 7.4 and 1 mM ATP. To each well were added 50 \u03bcl scintillant liquid and the radioactivity of the samples was measured on Scintilation counter (Topcount, HP). The IC50 values of different peptides were calculated using GraFit software. </p> Phosphorylation of Histone </p> Histone 1 phosphorylation induced by CDK2/Cyclin E and CDK1/Cyclin B was measured using similar method. The concentration of Histone 1 in the kinase reaction was 1 mg/ml (unless different stated). The kinase reaction was stopped by 75 mM Phosphoric acid (100 \u03bcl per well) and the reaction mixture was transferred onto P81 plates. The plates were washed 3 times with 200 \u03bcl 75 mM orthophosphoric acid. </p> Protein Kinase C (PKC) \u03b1 Assay </p> PKC\u03b1 kinase activity was measured by the incorporation of radio-labeled phosphate in Histone 3. The reaction mixture (total volume 65 \u03bcl) consist of 50 mM Tris-HCl, 1 mM Calcium acetate, 3 mM DTT, 0.03 mg/ml Phosphatidylserine, 2.4 \u03bcg/ml PMA, 0.04% NP40, 12 mM Mg/Cl, purified PKC\u03b1-100 ng, Histone 3, 0.2 mg/ml, 100 \u03bcM ATP, 0.2 \u03bcCi [\u03b3-<sup>32</sup>P]-ATP. The reaction was carried over 15 min at 37\u00b0 C. in microplate shaker and was stopped by adding 10 \u03bcl 75 mM orthophosphoric acid and placing the plate on ice. 50 \u03bcl of the reaction mixture was transferred onto P81 filterplate and after washing off the free radioactive phosphate (3 times with 200 \u03bcl 75 mM orthophosphoric acid per well) 50 \u03bcl of scintillation liquid (Microscint 40) were added to each well and the radioactivity was measured on Scintillation counter (Topcount, HP). </p> ERK-2 (MAP Kinase) Assay </p> ERK-2 kinase activity was measured by the incorporation of radio-labeled phosphate into Myelin Basic Protein (MBP), catalyzed by purified mouse ERK2 (Upstate Biotecnoligies). The reaction mixture (total volume 50 \u03bcl) consisted of 20 mM MOPS, pH 7.0, 25 mM \u03b2-glycerophosphate, 5 mM EGTA, 1 mM DTT, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM MgCl, 100 \u03bcM ATP, 0.2 \u03bcCi [\u03b3-<sup>32</sup>P]-ATP. </p> CDK2/Cyclin A </p> CDK2/cyclin A kinase assays were performed in 96-well plates using recombinant CDK2/cyclin A. Assay buffer consisted of 25 mM \u03b2-glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM NaVO<sub>3</sub>, pH 7.4, into which was added 2-4 \u03bcg of CDK2/cyclin A with substrate pRb(773-928). The reaction was initiated by addition of Mg/ATP mix (15 mM MgCl<sub>2</sub>, 100 \u03bcM ATP with 30-50 kBq per well of [\u03b3-<sup>32</sup>P]-ATP) and mixtures incubated for 10-30 min, as required, at 30\u00b0 C. Reactions were stopped on ice, followed by filtration through p81 filterplates (Whatman Polyfiltronics, Kent, UK). After washing 3 times with 75 mM orthophosphoric acid, plates were dried, scintillant added and incorporated radioactivity measured in a scintillation counter (TopCount, Packard Instruments, Pangbourne, Berks, UK). </p> Competitive Cyclin D1/Cyclin A Binding Assay (ELISA). </p> Biotinylated p21 (149-159)\u2014DFYHSKRRLIF was immobilized on Streptavidin coated 96-well plates (PIERCE). Different amounts of a competitor peptide were mixed with Cyclin D1/Cyclin A and than loaded onto the plate with immobilized biotinylated p21 (149-159). The amount of bound Cyclin D1/Cyclin A was immunodetected and quantified by Turbo-ELISA reagent (PIERCE). The IC 50 values (a concentration of the competitor peptide which inhibits 50% of Biotin-p21 (149-159)\u2014Cyclin D1/Cyclin A binding) were calculated using GraFit software. </p> Cyclin A Binding Assay </p> Streptavidin-coated plates (Reacti-Bind\u2122, Pierce) were washed three times with TBS/BSA buffer (25 mM Tris-HCl, 150 mM NaCl pH 7.5, 0.05% Tween-20, 0.1% BSA; 200 \u03bcL) for 2 min each. A 10 mM stock solution of biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2 </sub>was diluted to 0.5 \u03bcM with TBS/BSA buffer. This was added to each well (100 \u03bcL). The plate was incubated for 1 h at room temperature with constant shaking. The plate was washed once quickly with TBS/BSA buffer (200 \u03bcL), followed by three more washes with TBS/BSA buffer (200 \u03bcL) for 5 min each. Serial dilutions of test peptides were prepared in a new plate (50 \u03bcL in each well). Cyclin A was diluted to 5 \u03bcg/50 \u03bcL with TBS/BSA buffer and this was then added to each well (50 \u03bcL). The solutions were mixed thoroughly with a pipette (5-6 times), before being incubated for 30 min at room temperature. This reaction mixture was then transferred to the biotinylated peptide:streptavidin-coated plate and incubated for 1 h at room temperature with constant shaking. The plate was washed once quickly with TBS/BSA buffer (200 \u03bcL), followed by three more washes with TBS/BSA buffer (200 \u03bcL) for 5 min each. The cyclin A antibody (Santa Cruz polyclonal) solution was diluted 1:200 with TBS/BSA buffer and this was then added to each well of the plate (100 \u03bcL. The plate was incubated for 1 h at room temperature with constant shaking. The plate was washed once quickly with TBS/BSA buffer (200 \u03bcl), followed by three more",
    "p21(145-164). The in vitro effect of these peptides on CDK4/cyclin D1 and CDK2/cyclin E kinase activity in terms of inhibition of phosphorylation of GST-pRb-was investigated. </p> We have demonstrated that a shorter sequence being a 12 amino acid peptide DFYHSKRRLIFS\u2014p21 (149-160) appeared to have very similar activity as the original 20-mer peptide of Ball et al., with respect to in vitro inhibitory activity in vitro CDK4-Cyclin-D1 kinase. </p> A detailed SAR analysis of p21 (149-160) was done in 96-well format CDK4-Cyclin D1 kinase assay using different peptide derivatives\u2014truncations and alanine substitutions. In order to determine the relative importance of each position of the 12 amino acid peptide which contained the binding domain, we synthesised p21(149-160) derivatives, where each residue was sequentially substituted with Ala. The effect of the peptide mutations on their kinase inhibitory activity was then tested. Ala substitution of Phe<sup>150</sup>, Tyr<sup>151</sup>, His<sup>152</sup>, Ile<sup>158</sup>, and Ser<sup>160 </sup>did not change significantly the CDK2/cyclin E inhibitory activity of p21(149-160). Substitution of Ser<sup>153 </sup>with Ala increased 100-fold the inhibitory potency of p21(149-160) towards CDK2/cyclin E. The results are shown in Table 1. </p> SAR of p21 (149-160) in CDK2/Cyclin E Kinase Assay. </p> P21 (141-160) peptide was shown to inhibit CDK2-Cyclin E induced phosphorylation of GST-Rb (Ball et al., 1995) at concentration 40 times its IC50 of CDK4/cyclin D1. The results herein show that a truncated form- p21 (149-160) and variants thereof, retain very good potency to inhibit the CDK2-Cyclin E induced phosphorylation of GST-Rb and in many cases the peptides were shown to be preferentially inhibitory of CDK2 as opposed to CDK4. Detailed SAR of p21 (149-160) were determined in CDK2-Cyclin E in vitro kinase assay. The data are shown in Table 1. </p> A comparison between the SAR of p21 (149-160) in CDK2-Cyclin E and CDK4-Cyclin D1 kinase assays shows a higher inhibitory activity towards CDK2-Cyclin E than to CDK4-Cyclin D1. Alanine mutation of Ser153 increases 100 fold the potency of the peptide to inhibit the CDK2-Cyclin E but has little effect on CDK4-Cyclin D1 induced phosphorylation of GST-Rb. For both inhibitory activities of p21 (149-160) the most important residues are Arg155, Leu 157 and Phe 159. The CDK4-Cyclin D1 inhibitory activity of p21 (149-160) tolerates less changes than the CDK2-Cyclin E one. </p> Using identical assays, the sequence p21(148-159) was shown to be active against both CDK2/cyclin E and CDK4/cyclin D1.  \nTABLE 1Structure-activity relationships of p21 (145-164) peptides with respectto inhibition of cyclin E/CDK2 and cyclin D1/CDK4p21 <sup>WAFI</sup> Sequence<sup>a</sup>RP-HPLC<sup>c</sup>145150155160164MS<sup>b</sup>l<sub>R</sub>PurityTSMTDFYHSKRRLIFSKRKPFormulaM,[M + H](min)(%)TSMTDFYHSKRRC<sub>65</sub>H<sub>102</sub>N<sub>22</sub>O<sub>19</sub>S1527.711530.311.055.7 SMTDFYHSKRRLC<",
    "bstrate. </p> Effect of p21 (149-160) and its Derivatives on CDK1-Cyclin B Kinase Activity. </p> p21(149-160) and its derivatives were tested for ability to inhibit CDK1/cyclin B kinase activity in phosphorylating histone H1 or GST-pRb (Table 2). p21(149-160) and its Ala mutant p21(149-160) Ser153Ala did not have any significant effect on the CDK1/cyclin B-induced phosphorylation of histone H1. None of the tested peptides were able to inhibit significantly the CDK1/cyclin B-induced phosphorylation of GST-pRb and only the highest peptide concentrations used (200 \u03bcM) had a marginal inhibitory effect on CDK1/cyclin B kinase activity. When tested in the \u201cpull-down\u201d assay, immobilised p21(149-160) was unable to precipitate cyclin B either as a monomer, or as a complex with CDK1. These data coincide with the very poor inhibitory activity of the original 20 mer p21(141-160) peptide (Ball, K. L.; Lain, S.; F{dot over (a)}hraeus, R.; Smythe, C.; Lane, D. P. Curr. Biol. 1996, 7, 71-80) and the full-length p21<sup>WAF1 </sup>protein towards CDK1/cyclin B complex (Harper, J. W.; Elledge, S. J.; Keyomarsi, K.; Dynlacht, B.; Tsai, L. H.; Zhang, P.; Dobrowolski, S.; Bai, C.; Connell-Crowley, L.; Swindell, E.; et al. Molec. Biol. Cell 1995, 6, 387-400) and show that p21(149-160) and its derivatives retain the selectivity of the full-length protein.  \nTABLE 2Inhibition of CDK1-Cyclin B induced phosphorylation of Histone1 and GST-Rb by p21 derived peptides.HistoneGST-RbPeptideSequenceIC50 [\u03bcM]IC50 [\u03bcM]P21 (149-160)DFYHSKRRLIFS&gt;200200P21 (149-160)153ADFYHAKRRLIFS200&gt;200P21 (149-159)DFYHSKRRLIFNot tested&gt;200\n\n Effect of Purified P21<sup>WAF1 </sup>on CDK4-Cyclin D1 and CDK2-Cyclin E Kinase Activity \n</p> In order to evaluate the selectivity, specificity and potency of p21 (149-160) and its derivatives we compared their effect with the one of purified p21 on kinase activity of CDK2-Cyclin E and CDK4-Cyclin D1. The IC 50 values characterizing the inhibition of CDK4-Cyclin D1 and CDK2-Cyclin E induced phosphorylation of GST-Rb and CDK2-Cyclin E induced phosphorylation of Histonel by purified p21<sup>WAF1 </sup>are shown in Table 3. The IC 50 of the most active peptide\u2014p21 (149-160) 153A for CDK2-Cyclin E induced phosphorylation of GST-Rb was 40 nM which is approximately 50 fold higher than the IC 50 value for p21<sup>WAF1</sup>. Purified p21 though, inhibited strongly the CDK2-Cyclin E induced phosphorylation of GST-Rb as well as Histone 1. The peptides derived from p21<sup>WAF1</sup>-p21 (149-160) and p21 (149-160)153A peptides specifically inhibit the GST-Rb phosphorylation, but do not inhibit the Histone 1 phosphorylation induced by CDK2-Cyclin E. This substrate specific effect of p21 (149-160) and its derivatives strongly suggest a mechanism of competitive binding of the peptide inhibitors and Rb to CDK2-Cyclin E or CDK4-Cyclin D1. The fact that p21 (149-160) and its derivatives did not inhibit significantly the CDK1-Cyclin B induced phosphorylation of GST-Rb excludes a possibility for direct binding of the peptide to the substrate (see Table 2).  \nTABLE 3Inhibition of CDK4-Cyclin D1 and CDK2-Cyclin E kinase activity bypurified p21<sup>WAF1</sup>Inhibition by p21<sup>WAF1</sup>Kinase complexSubstrateIC50 [nM]CDK4-Cyclin D1GST-Rb(772-928)6.5 \u00b1 0.8CDK2-Cyclin EGST-Rb(772-928)0.7 \u00b1 0.2CDK2-Cyclin EHistone 11.8 \u00b1 0.4\n</p>Example 7 P21 (149-160) and its Derivatives do not Inhibit PKC\u03b1 and ERK2 Kinase Activity in vitro  To investigate further the specificity of p21 (149-160) and its derivatives we investigated the effect of the strongest inhibitors of CDK2-Cyclin E and CDK4-Cyclin D1 complexes on PKC \u03b1 and ERK2 kinase activity (Table 4). None of the tested peptides (at concentrations up to 100 \u03bcM) had any inhibitory effect on PKC\u03b1 phosphorylation of Histone 3 or ERK2",
    "us, p27, E2F1 and p107 (Table 5). </p> The main results as presented in Table 5 below, are: \n 1. All peptides inhibited CDK2-Cyclin and were much less potent toward CDK4/Cyclin D1 kinase activity.  2. CDK2/Cyclin A and CDK2/Cyclin E were inhibited with similar potency by the 8-mers with the exception of HAKRRLIF and KAURRLIF which were 10 fold more potent toward CDK2/Cyclin A than to CDK2/Cyclin E kinase activity.  3. In the context of eight amino acid peptides alanine substitution of Ser153 led to significant increase of the kinase inhibitory potency of p21 (152-159)\u2014100, 10 and 4 fold toward CDK2/Cyclin A, CDK2/Cyclin E and CDK4/Cyclin D1 phosphorylation of pRb respectively.  4. The most potent inhibitors of pRb phosphorylation contain Ala on the second position and LIF motif; they are followed by the peptides containing Ala on the second position and LFG motif (with the exception of the p27 derived peptide which contain Gln instead of Arg on the 5<sup>th </sup>position ), Ser and LFG, and Ser and LIF containing peptides. The least potent were LDL containing peptides. \n</p> These results manifest the importance of Ala and LIF motif for the kinase inhibitory potency of the peptides. </p> Competitive Binding of Peptides, Containing Different Motifs (LIF, LFG, LDL) to Cyclin A or Cyclin D1. </p> The next important question was if these peptides share the same kinase inhibitory mechanism (bind to the same Cyclin docking site). To answer this question we developed a competitive binding assay where the influence of the 8-mers on Cyclin A (D1)\u2014p21 (149-159) binding was studied (See Materials and Methods for more details). </p> The results from Cyclin D1 competitive binding assay are summarized on Table 6. For easy comparison, the data for CDK4/Cyclin D1 kinase inhibitory activity of the peptides are given in the same table.  \nTABLE 5Kinase inhibitory activity of LDL, LIF and LFG containing peptides, derivedfrom E2F, p107, p21 N- and C-terminus and p27.Kinase InhibitionCyclin A/CDK2Cyclin E/CDK2Cyclin D1/CDK4Cyclin D1/CDK6Competitive binding<sup>b</sup>IC<sub>50</sub>%IC<sub>50</sub>%IC<sub>50</sub>%IC<sub>50</sub>%Cyclin ACyclin D1PeptideSequence<sup>a</sup>(\u03bcM)Inhibition(\u03bcM)Inhibition(\u03bcM)Inhibition(\u03bcM)InhibitionIC<sub>50 </sub>(\u03bcM)IC<sub>50 </sub>(\u03bcM)p21 C-terminusHSKRRLIF3.4803.4802172n/dn/dn/d48p21 C-terminusHAKRRLIF0.021880.3581\u20026825.81000.313(S153A)p21 C-terminus - LFGHSKRRLFG1.4781.682n/a42n/dn/d4.4&gt;200hybridp21 C-terminus - LDLHSKRRLDL5.4783974n/a24n/dn/d5.8&gt;200hybridp21 C-terminusHAKRRLFG0.67780.9823070n/dn/d0.3533(S153A) LFGE2F1PVKRRLDL1.2802.1749958n/dn/d1.2&gt;100p27SAURNLFG6.180282n/a46n/dn/d3.8&gt;200p107SAKRRLFG0.73750.5861778n/dn/d0.5124p21 N-terminusKAURRLFG0.54800.074864266n/dn/d0.75134p21 N-terminus - LIFKAURRLIF0.062701.2781383n/dn/d0.320hybrid<sup>a</sup>All peptides were synthesised with free amino termini and as the C-terminal carboxamides <sup>b</sup>Using the immobilised p21(149-159) peptide biotinyl-Ahx-Asp-Phe-Tyr-His-Ser-Lys-Arg-Arg-Leu-Ile-Phe-NH \n</p> We have demonstrated a very good agreement between the CDK4/Cyclin D1 kinase inhibition and Cyclin D1 competitive binding capabilities of the tested pept",
    "ete with Biotin-DFYHSKRRLIF for binding to Cyclin D1. However, peptides, containing LFG motif and Ala on second position were able to inhibit CDK4/Cyclin D1 and to compete with Biotin-DFYHSKRRLIF for binding to Cyclin D1. The only exception of this rule is p27 derived peptide\u2014SAURNLFG, where one of the important Arg residues is replaced with Asn. These results suggest that LFG and LIF peptides bind to the same site of Cyclin D1. </p> The results for Cyclin A competitive binding and CDK2/Cyclin A kinase inhibition of the peptides, containing LIF, LFG and LDL motifs are also shown in Table 5. There is a very good correlation between the CDK2/Cyclin A inhibition and Cyclin A binding capabilities of the tested peptides. The most potent inhibitor and strongest binding competitor was HAKRRLIF peptide. </p> Specificity and Selectivity of HAKRRLIF Kinase Inhibitory Activity. </p> Similarly to p21 (149-160) its derivative p21 (152-159)S153A was not able to inhibit Histone phosphorylation by CDK2/Cyclin A(E) complexes (data not shown). HAKRRLIF was not effective as an inhibitor in CDK1/Cyclin B in vitro kinase assay with Histone or Rb as substrates. HAKRRLIF did not inhibit PKC\u03b1 induced phosphorylation of Histones. </p> Thus, we have defined a 8-amino acid peptide derived for p21 (C-terminus) with a single point mutation\u2014S153A which has significantly higher kinase inhibitory activity than the original sequence. HAKRRLIF inhibited most strongly CDK2/Cyclin A phosphorylation of pRb\u2014with IC 50 of 20 nM. The inhibitory activity of the peptide correlates with its ability to bind the cyclin sub-unit. HAKRRLIF is very selective and specific kinase inhibitor\u2014it inhibits specificly only the pRb phosphorylation activity of G1 CDK/Cyclins and does not inhibit the mitotic CDK/Cyclins\u2014CDK1/Cyclin B (or A), or PKC \u03b1. HAKRRLIF has much higher specificity and selectivity than the full length p21 protein, which inhibits the Histone phosphorylation of CDK2/Cyclin kinases complexes and has some activity toward CDK1/Cyclin B. </p>Example 10 Competitive Cyclin A Binding of p21- and pRb(866-880)/pRb(870-877) Peptides  It has been shown (Adams, P. D.; Li, X.; Sellers, W. R:; Baker, K. B.; Leng, X.; Harper, J. W.; Taya, Y.; Kaelin, W. G. J. Molec. Cell. Biol. 1999, 19, 1068-1080) that pRb contains a cyclin-binding motif in its C-terminus and that this motif is required for the protein's phosphorylation. To test if the mechanism of kinase inhibition of the p21(152-159)Ser153Ala peptide was indeed via competition with pRb for binding to the cyclin subunit, we compared two synthetic pRb-derived peptides\u2014pRb(866-880) and pRb(870-877), as well as the recombinant GST-pRb(772-928) used in our kinase assays (all containing the cyclin-binding motif) with p21-derived peptides for binding to cyclin A. Table 6 shows that all three pRb-derived peptides were able to compete with the p21-derived peptides for binding to cyclin A, and vice versa. Interestingly, the longer synthetic peptide pRb(86",
    "n pRb(870-877). Probably the conformation of the latter peptide is more favourable for cyclin binding. This peptide contains a C-terminal Phe, which case was found considerably to enhance the kinase inhibitory and cyclin-binding activity in the case of the p21-derived peptides.  \nTABLE 6Competitive cyclin A binding of p21- and pRb(866-880)/pRb(870-877)peptidesCompetitive cyclin ARP-HPLC<sup>b</sup>binding IC<sub>50 </sub>(\u03bcM)MS<sup>a</sup>PurityimmobilisedimmobilisedCompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)pRb peptide<sup>c</sup>p21 peptide<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>0.20.02H-Asp-Phe-Tyr-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>70</sub>H<sub>105</sub>N<sub>21</sub>O<sub>14</sub>1464.71466.015.8<sup>i</sup>&gt;950.1n/dH-Ser-Asn-Pro-Pro-Lys-Pro-Leu-Lys-Lys-Leu-Arg-Phe-Asp-Ile-C<sub>82</sub>H<sub>137</sub>N<sub>23</sub>O<sub>21</sub>1781.11780.018.1<sup>ii</sup>&gt;953548Glu-NH<sub>2</sub>H-Lys-Pro-Leu-Lys-Lys-Leu-Arg-Phe-NH<sub>2</sub>C<sub>50</sub>H<sub>89</sub>N<sub>15</sub>O<sub>8</sub>1028.31026.017.0<sup>iii</sup>&gt;950.624GST-pRb(772-928)<sup>e</sup>n/d9<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac 218TP54, 1 mL/min, 25\u00b0 C., \u03bb = 214 nm; <sup>i </sup>0-40% <sup>ii </sup>15-25% <sup>iii </sup>10.5-20.5% MeCN in 0.1% aq CF<sub>3</sub>COOH over 20 min <sup>c</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-Lys-Pro-Leu-Lys-Lys-Leu-Arg-Phe-NH<sub>2</sub><sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>e</sup>Recombinant protein \n</p>Example 11 Competitive Binding of p21<sup>WAF1 </sup>and H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2 </sub>to Cyclin A in the Presence and Absence of CDK2  p21<sup>WAF1 </sup>contains two cyclin-binding sites, one each in its N- and C-terminus [(p21(19-23) and p21(154-159)], as well as a CDK2-binding site [p21(46-65)]. The cyclin A-binding affinities of full-length p21<sup>WAF1 </sup>and the peptide containing only the C-terminal cyclin-binding motif were compared in the presence and absence of CDK2. This showed (Table 7) that recombinant p21<sup>WAF1 </sup>had ca. 27-fold lower affinity than H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2 </sub>for cyclin A alone. When cyclin A was pre-complexed with CDK2, on the other hand, the apparent binding affinity of p21<sup>WAF1 </sup>increased and was comparable to that of the octapeptide. The increased ability of p21<sup>WAF1 </sup>to compete with the octapeptide for binding to CDK2-complexed cyclin A is most probably due to the contribution of the CDK-binding motif present in the former. On the other hand, the presence of CDK2 slightly decreased the apparent binding affinity of H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2 </sub>for cyclin A, which could be due to some conformational changes of the substrate recognition site on the cyclin sub-unit upon binding of CDK2.  \nTABLE 7Competitive binding of p21<sup>WAF1 ",
    "-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-his-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31039.115.4961.70.9H-His-ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31042.515.3980.30.6H-His-Ala-lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31042.915.6100&lt;0.1&lt;0.1H-His-Ala-Lys-arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31041.615.299&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31041.115.299&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31041.017.6100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31040.518.1100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31039.717.11000.10.2<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2 </sub>\n Residue Substitutions \n</p>Example 13 His<sup>152 </sup> This residue is comparatively insensitive to substitution. With the exception of Pya, all residue substitutions were either tolerated or even lead to enhanced binding and/or kinase inhibition potency. Furthermore, this residue can be truncated without significant loss in biological activity. </p>Example 13 Substitutions of His<sup>152 </sup>Residue in p21(152-159)Ser153Ala RP-HPLC<sup>b</sup>Relative activityMS<sup>a</sup>PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>11H-Ala-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>80</sub>N<sub>16</sub>O<sub>8</sub>973.2975.415.4981.82.5H-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>42</sub>H<sub>75</sub>N<sub>15</sub>O<sub>7</sub>902.1901.015.510010.3H-Pya-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>84</sub>N<sub>16</sub>O<sub>8</sub>1049.31050.615.498&lt;0.10.2H-Thi-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>49</sub>H<sub>82</sub>N<sub>16</sub>O<sub>8</sub>S1055.31055.516.310020.4H-Hse-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>82</sub>N<sub>16</sub>O<sub>9</sub>1003.31002.915.78222H-Phe-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>84</sub>N<sub>16</sub>O<sub>8</sub>1049.31052.316.310031H-Dab-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>83</sub>N<sub>17</sub>O<sub>8</sub>1002.31004.715.510050.4<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 14 Ala<sup>153 </sup> This is the residue position where replacement of the native Ser with Ala resulted in a dramatic potency increase. Further potency enhancements are observed when short, straight-chain (Abu) or \u03b2-branched (Val, Bug) residues are introduced. Side chains containing more than three saturated carbon atoms in a straight chain are poorly tolerated. </p>Example 14 Substitutions of Ala<sup>153 </sup>Residue in p21(152-159)Ser153Ala RP-HPLC<sup>b</sup>Relative activityMS<sup>a</sup>PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>11H-His-Gly-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1025.31026.815.2980.10.1H-His-Abu-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>49</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1053.31055.215.810051.3H-His-Nva-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>50</sub>H<sub>86</sub>N<sub>18</sub>O<sub>8</sub>1067.31069.116.0100&lt;0.1&lt;0.1H-His-Bug-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>88</sub>N<sub>18</sub>O<sub>8</sub>1081.41082.715.91000.21.2H-His-Val-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>50</sub>H<sub>86</sub>N<sub>18</sub>O<sub>8</sub>1067.31068.515.910021.7H-His-Ile-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>88</sub>N<sub>18</sub>O<sub>8</sub>1081.41081.916.11000.50.2H-His-Phg-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>53</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1101.41101.815.8, 16.1<sup>e</sup>100&lt;0.1&lt;0.1H-His-Phe-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>54</sub>H<sub>86</sub>N<sub>18</sub>O<sub>8</sub>1115.41115.816.51000.50.2<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>e</sup>Mixture of diastereomers (racemic Fmoc-Phg-OH used) </p>Example 15 Lys<sup>154 </sup> Various non-isosteric replacements are tolerated to some extent. A significant potency increase is observed when the conservative Lys-to-Arg replacement is made. </p>Example 15 Substitutions of Lys<sup>154 </sup>Residue in p21(152-159)Ser153Ala RP-HPLC<sup>b</sup>Relative activityMS<sup>a</sup>PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Ala-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>75</sub>N<sub>17</sub>O<sub>8</sub>982.2983.615.699&lt;0.10.5H-His-Ala-Nle-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>17</sub>O<sub>8</sub>1024.31022.916.8970.30.2H-His-Ala-Abu-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>77</sub>N<sub>17</sub>O<sub>8</sub>996.2997.416.11000.80.2H-His-Ala-Leu-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>17</sub>O<sub>8</sub>1024.31025.516.8970.11.4H-His-Ala-Arg-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>20</sub>O<sub>8</sub>1067.31067.915.5945.71.5<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 16 Arg<sup>155 </sup> Only the conservative replacements with Cit and Lys are tolerated to some extent. </p>Example 16 Substitutions of Arg<sup>155 </sup>Residue in p21(152-159)Ser153Ala RP-HPLC<sup>b</sup>Relative activityMS<sup>a</sup>PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Lys-Ala-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>75</sub>N<sub>15</sub>O<sub>8</sub>954.2954.916.095&lt;0.1&lt;0.1H-His-Ala-Lys-Cit-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>17</sub>O<sub>9</sub>1040.31053.512.5940.20.2H-His-Ala-Lys-Hse-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>77</sub>N<sub>15</sub>O<sub>9</sub>984.2985.915.8100&lt;0.1&lt;0.1H-His-Ala-Lys-His-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>77</sub>N<sub>17</sub>O<sub>8</sub>1020.21022.115.498&lt;0.1&lt;0.1H-His-Ala-Lys-Nle-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>15</sub>O<sub>8</sub>996.3998.418.186&lt;0.1&lt;0.1H-His-Ala-Lys-Gln-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>78</sub>N<sub>16</sub>O<sub>9</sub>1011.21012.915.698&lt;0.1&lt;0.1H-His-Ala-Lys-Lys-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>16</sub>O<sub>8</sub>1011.31011.815.31000.80.1<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 17 Arg<sup>156 </sup> This residue was probed with replacements constraining the backbone dihedral angles in different ways (Ala, Pro, Aib, Sar), none of which were tolerated. Partially tolerated replacements with Cit or Ser indicate involvment in H-bonding. </p>Example 17 Substitutions of Arg<sup>156 </sup>Residue in p21(152-159)Ser153Ala RP-HPLC<sup>b</sup>Relative activityMS<sup>a</sup>PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>[M + H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Lys-Arg-Ala-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>75</sub>N<sub>15</sub>O<sub>8</sub>954.2954.516.1100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Asn-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>76</sub>N<sub>16</sub>O<sub>9</sub>997.2997.515.599&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Pro-Leu-Ile-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>77</sub>N<sub>15</sub>O<sub>8</sub>980.2980.116.3100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Ser-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>75</sub>N<sub>15</sub>O<sub>9</sub>970.2970.216.11000.70.2H-His-Ala-Lys-Arg-Aib-Leu-Ile-Phe-NH<sub>2</sub>C<sub>46</sub>H<sub>77</sub>N<sub>15</sub>O<sub>8</sub>968.2968.116.773&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Sar-Leu-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>75</sub>N<sub>15</sub>O<sub>8</sub>954.2955.416.5100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Cit-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>17</sub>O<sub>9</sub>1040.31041.4215.671000.3n/d<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 18 Leu<sup>157 </sup> This residue is very sensitive to replacement, even with nearly isosteric groups. Only the very conservative Leu-to-Ile replacement was tolerated somewhat. </p>Example 18 Substitutions of Leu<sup>157 </sup>Residue in p21(152-159)Ser153Ala MS<sup>a</sup>RP-HPLC<sup>b</sup>Relative activity[M +PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Lys-Arg-Arg-Ala-Ile-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>76</sub>N<sub>18</sub>O<sub>8</sub>997.2996.913.9100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31041.015.1100&lt;0.10.1H-His-Ala-Lys-Arg-Arg-Ile-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31041.114.41001.50.2H-His-Ala-Lys-Arg-Arg-Val-Ile-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1025.31026.215.8100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Nle-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31040.215.8100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Nva-Ile-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1025.31025.014.9100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Cha-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>86</sub>N<sub>18</sub>O<sub>8</sub>1079.41079.217.5100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Phe-Ile-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1073.31072.716.4100&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-1Nap-Ile-Phe-NH<sub>2</sub>C<sub>52</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1123.41122.517.9100&lt;0.1&lt;0.1<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 19 Ile<sup>158 </sup> All substitutions with aliphatic and aromatic residues were tolerated to some extent. However, excision of the Ile residue abolished activity. These results indicate that this residue is not crucial for activity but may be important as a spacer group between the flanking Leu and Phe groups. </p>Example 19 Substitutions of Ile<sup>158 </sup>Residue in p21(152-159)Ser153Ala MS<sup>a</sup>RP-HPLC<sup>b</sup>Relative activity[M +PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Lys-Arg-Arg-Leu-Ala-Phe-NH<sub>2</sub>C<sub>45</sub>H<sub>76</sub>N<sub>18</sub>O<sub>8</sub>997.2996.513.81000.30.8H-His-Ala-Lys-Arg-Arg-Leu-Leu-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31038.416.11001.20.6H-His-Ala-Lys-Arg-Arg-Leu-Val-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1025.31024.714.91000.81.5H-His-Ala-Lys-Arg-Arg-Leu-Nle-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31040.316.31000.40.3H-His-Ala-Lys-Arg-Arg-Leu-Nva-Phe-NH<sub>2</sub>C<sub>47</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1025.31025.715.21000.20.6H-His-Ala-Lys-Arg-Arg-Leu-Cha-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>86</sub>N<sub>18</sub>O<sub>8</sub>1079.41080.218.41000.30.5H-His-Ala-Lys-Arg-Arg-Leu-Phe-Phe-NH<sub>2</sub>C<sub>51</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1073.31073.916.31000.40.4H-His-Ala-Lys-Arg-Arg-Leu-1Nap-Phe-NH<sub>2</sub>C<sub>55</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1123.41122.918.21000.50.5H-His-Ala-Lys-Arg-Arg-Leu-Phe-NH<sub>2</sub>C<sub>42</sub>H<sub>71</sub>N<sub>17</sub>O<sub>7</sub>926.1924.813.8100&lt;0.1&lt;0.1<sup>a</sup>DE MALDI-TOF MS. +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 20 Phe<sup>159 </sup> Only certain replacements with aromatic residues were tolerated. Notably pFPhe substitution resulted in an analogue with enhanced cyclin A-binding affinity. </p>Example 20 Substitutions of Phe<sup>159 </sup>Residue in p21(152-159)Ser153Ala MS<sup>a</sup>RP-HPLC<sup>b</sup>Relative activity[M +PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-His-Ala-Lys-Arg-Arg-Leu-Ile-Leu-NH<sub>2</sub>C<sub>45</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1005.31005.714.2970.3&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-Cha-NH<sub>2</sub>C<sub>48</sub>H<sub>88</sub>N<sub>18</sub>O<sub>8</sub>1045.31045.516.9100&lt;0.10.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-Hof-NH<sub>2</sub>C<sub>49</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1053.31052.815.896&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-Tyr-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>9</sub>1055.31054.613.31000.30.2H-His-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>18</sub>O<sub>8</sub>1057.31055.816.010015H-His-Ala-Lys-Arg-Arg-Leu-Ile-mFPhe-NH<sub>2</sub>C<sub>48</sub>H<sub>81</sub>N<sub>18</sub>O<sub>8</sub>1057.31055.516.21000.80.8H-His-Ala-Lys-Arg-Arg-Leu-Ile-Trp-NH<sub>2</sub>C<sub>50</sub>H<sub>83</sub>N<sub>19</sub>O<sub>8</sub>1078.31076.115.6980.30.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-1Nap-NH<sub>2</sub>C<sub>52</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1089.31090.717.81000.2&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-2Nap-NH<sub>2</sub>C<sub>52</sub>H<sub>84</sub>N<sub>18</sub>O<sub>8</sub>1089.31090.618.01001.20.7H-His-Ala-Lys-Arg-Arg-Leu-Ile-Lys-NH<sub>2</sub>C<sub>45</sub>H<sub>85</sub>N<sub>19</sub>O<sub>8</sub>1020.31021.511.666&lt;0.1&lt;0.1H-His-Ala-Lys-Arg-Arg-Leu-Ile-Tic-NH<sub>2</sub>C<sub>49</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1051.31052.315.6910.3&lt;0.1<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 21 Substitutions of Phe<sup>159 </sup>Residue in p21(152-159)Ser153Ala with Conformationally Defined Residues  Fmoc-DL-threo-Pse-OH </p> To a solution of H-DL-threo-Pse-OH (1 g, 5.5 mmol) in 5% aq Na<sub>2</sub>CO<sub>3 </sub>(13 mL, 6 mmol), was added a solution of Fmoc-ONSu (1.7 g, 5 mmol) in THF (13 mL) over a period of 30 min. The mixture was stirred vigorously for 5 h. The solvent was evaporated to dryness in vacuo. The residual white solid was dissolved in H<sub>2</sub>O (150 mL) and was washed with Et<sub>2</sub>O (2\u00d7100 mL). The aqueous phase was acidified to pH 2 with 0.2 M aq HCl and a precipitate was obtained, which was extracted into EtOAc (2\u00d7100 mL). The combined extracts were washed with aq KHSO<sub>4 </sub>and brine, dried (MgSO<sub>4</sub>) and concentrated in vacuo to afford a crude product (1.32 g, 65%). This was dissolved in the minimum volume of EtOAc and dripped into vigorously stirred hexane to afford, after filtration and drying, the title compound (1.27 g, 63%). M.p. 107-108\u00b0 C. TLC (EtOAc/AcOH, 99:1): R<sub>f</sub>=0.27. RP-HPLC (Vydac 218TP54, 1 mL/min, 50-100% MeCN in 0.1% aq CF<sub>3</sub>COOH over 20 min): t<sub>R</sub>=7.2 min. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 250 MHz), \u03b4. 7.75 (2H, d, J=7.6 Hz, Fmoc aromatic H), 7.42-7.49 (2h, M, Fmoc aromatic H), 7.27-7.39 (9H, m, aromatic H), 5.67 (1H, d, J=9.0 Hz, NH), 5.45 (1H, d, J=2.4 Hz, C<sup>\u03b2</sup",
    " OHC<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>10</sub>1071.31074.18.899&lt;0.1&lt;0.1H-His Ser Lys Arg Arg Leu Ile D-Pse OHC<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>10</sub>1071.31073.06.899&lt;0.1&lt;0.1H-His Ala Lys Arg Arg Leu Ile L-Psa OHC<sub>50</sub>H<sub>84</sub>N<sub>18</sub>O<sub>10</sub>1097.31098.011.29922n/dH-His Ala Lys Arg Arg Leu Ile D-Psa OHC<sub>50</sub>H<sub>84</sub>N<sub>18</sub>O<sub>10</sub>1097.31098.08.499&lt;0.1n/dH-His Ser Lys Arg Arg Leu Ile L-Psa OHC<sub>50</sub>H<sub>84</sub>N<sub>18</sub>O<sub>11</sub>1113.31114.910.899&lt;0.1n/dH-His Ser Lys Arg Arg Leu Ile D-Psa OHC<sub>50</sub>H<sub>84</sub>N<sub>18</sub>O<sub>11</sub>1113.31114.4899&lt;0.1n/dH-His Ala Lys Arg Arg Leu Ile Dhp OHC<sub>48</sub>H<sub>80</sub>N<sub>18</sub>O<sub>8</sub>1037.31038.48.8993.30.2H-His Ser Lys Arg Arg Leu Ile Dhp OHC<sub>48</sub>H<sub>80</sub>N<sub>18</sub>O<sub>9</sub>1053.31054.68.8990.4n/dH-His Ala Lys Arg Arg Leu Ile PheolC<sub>48</sub>H<sub>83</sub>N<sub>17</sub>O<sub>8</sub>1026.31026.28.4990.61.0H-His Ser Lys Arg Arg Leu Ile PheolC<sub>48</sub>H<sub>83</sub>N<sub>17</sub>O<sub>8</sub>1042.31041.68.4950.2&lt;0.1<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>\n</p> As is clear from the results presented above, the Phe<sup>159 </sup>residue represents a key determinant in the p21(152-159) pharmacophore: its truncation abolishes activity and certain well-defined substitutions lead to enhanced potency. For this reason, further constriction of the Phe aromatic side chain may lock it into a bio-active conformation and further potency gains may be expected. Such conformational definition can be introduced in many different ways, e.g. through further substitution at C<sup>\u03b2</sup>(as in Psa and Pse), introduction of unsaturation, particularly between C<sup>\u03b1</sup>, and C<sup>\u03b2</sup>(as in Dhp), or by tethering of the aromatic system to the peptide backbone (C<sup>\u03b1</sup>and NH), as e.g. in Tic (refer structures below).  \n<img id=\"EMI-C00033\" path=\"US20060293245A1-20061228-C00033.TIF\" file=\"https://surechembl.org/api/assets/attachment/34184707/US/20061228/A1/020060/29/32/45/US20060293245A1-20061228-C00033.TIF\"/>\n</p> The resolution of \u03b2-hydroxy-\u03b1-amino acids by the action of proteases on a range of N-acyl methyl esters has been described (Ch\u00eanevert, R.; L\u00e9toumeau, M.; Thiboutot, S. Can. J Chem. 1990, 68, 960-963). Using a similar method, we resolved N-acetyl-DL-threo-phenylserine methyl ester into enantiomers of high optical purity by \u03b1-chymotrypsin-mediated enzymatic hydrolysis. Chymotrypsin is specific for the 2S-enantiomer that is typically found ",
    "Relative activity[M +PurityKinaseCyclin ACompoundFormulaM<sub>r</sub>H]<sup>+</sup>t<sub>R </sub>(min)(%)Inhibition<sup>c</sup>Binding<sup>d</sup>H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>11H-Ala-Ala-Abu-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>43</sub>H<sub>74</sub>N<sub>15</sub>O<sub>8</sub>F948.15948.1618.889960n/dH-Ala-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>42</sub>H<sub>72</sub>N<sub>13</sub>O<sub>9</sub>F922.11922.1117.829980n/dH-Ala-Ala-Lys-Arg-Cit-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>45</sub>H<sub>78</sub>N<sub>15</sub>O<sub>9</sub>F992.2922.216.949910n/dH-Ala-Ala-Lys-Arg-Arg-Leu-Ala-pFPhe-NH<sub>2</sub>C<sub>42</sub>H<sub>73</sub>N<sub>16</sub>O<sub>8</sub>F949.14949.6917.899920n/dH-Ala-Ala-Abu-Arg-Ser-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>40</sub>H<sub>67</sub>N<sub>12</sub>O<sub>9</sub>F879.04879.0516.569914n/dH-Ala-Ala-Lys-Gln-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>44</sub>H<sub>75</sub>N<sub>14</sub>O<sub>9</sub>F963.16963.1720.16994n/dH-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>42</sub>H<sub>75</sub>N<sub>15</sub>O<sub>7</sub>F902.15920.1416.6994n/d<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., 0-40% MeCN in 0.1% aq TFA over 20 min, \u03bb = 214 nm <sup>c</sup>CDK2/cyclin A kinase assay, pRb substrate, [ATP] = 100 \u03bcM <sup>d</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 23 Cyclic peptides  Inspection of the appropriate contacts in the complex structure of cyclin A with a p27<sup>KIPI </sup>fragment (Russo, A. A.; Jeffrey, P. D.; Patten, A. K.; Massague, J.; Pavletich, N. P. Nature 1996, 382, 325-31).; suggested a starting point for the design of such conformationally constrained peptides. Asn<sup>31 </sup>of the p27 sequence apparently participates in H-bonds not only to the cyclin groove, but also in intra-molecular H-bonding to Gly<sup>34</sup>. It was therefore plausible that peptide analogues containing macrocyclic constraints approximating this situation may be bio-active. One such cyclic peptide, in which Asn was replaced with Lys and an amide bond patched between its \u03b5-amino group and the carboxyl group of Gly, was designed and modelled (FIG. 3). </p> While molecular modelling suggested that this approach may work, the question remained whether a synthetic peptide containing the same constraint would indeed be bio-active. For this reason a convenient synthetic route based on an alkanesulfonamide safety-catch linker (Backes, B. J.; Ellman, J. A. J. Org. Chem. 1999, 64, 2322-2330) was developed for the synthesis of the desired \u2018side chain-to-tail\u2019 cyclic peptides as set out below;  \n<img id=\"EMI-C00035\" path=\"US20060293245A1-20061228-C00035.TIF\" file=\"https://surechembl.org/api/assets/attachment/34184697/US/20061228/A1/020060/29/32/45/",
    "sub>58</sub>N<sub>12</sub>O<sub>5</sub>702.9704.713.35<sup>iii</sup>995100H-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>39</sub>H<sub>70</sub>N<sub>14</sub>O<sub>6</sub>831.07832.812.63<sup>iii</sup>995100H-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>42</sub>H<sub>75</sub>N<sub>15</sub>O<sub>7</sub>902.15903.912.82<sup>iii</sup>992100H-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>C<sub>48</sub>H<sub>82</sub>N<sub>18</sub>O<sub>8</sub>1039.31040.412.91<sup>iii</sup>99\u2002\u20090.3100H-Asn-Leu-Phe-Gly-NH<sub>2</sub>C<sub>21</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>448.52449.618.14<sup>i</sup>99\u201480 (at 200 \u03bcM)H-Arg-Asn-Leu-Phe-Gly-NH<sub>2</sub>C<sub>27</sub>H<sub>44</sub>N<sub>10</sub>O<sub>6</sub>604.71605.217.17<sup>i</sup>99\u201420 (at 200 \u03bcM)H-Abu-Arg-Asn-Leu-Phe-Gly-NH<sub>2</sub>C<sub>31</sub>H<sub>51</sub>N<sub>11</sub>O<sub>7</sub>689.81690.912.87<sup>ii</sup>99\u2014\u2014H-Ala-Abu-Arg-Asn-Leu-Phe-Gly-NH<sub>2</sub>C<sub>34</sub>H<sub>56</sub>N<sub>12</sub>O<sub>8</sub>760.89761.413.61<sup>ii</sup>9925\u2002\u200290H-Ser-Ala-Abu-Arg-Asn-Leu-Phe-Gly-NH<sub>2</sub>C<sub>37</sub>H<sub>61</sub>N<sub>13</sub>O<sub>10</sub>847.97849.114.90<sup>ii</sup>9915\u2002100<sup>a</sup>DE MALDI-TOF MS, +ve mode, \u03b1-cyano-4-hydroxycinnamic acid matrix, calibration on authentic H-His-Ala-Lya-Arg-Arg-Leu Ile-Phe-NH<sub>2</sub><sup>b</sup>Vydac218TP54, 1 mL/min, 25\u00b0 C., MeCN gradient in 0.1% aq TFA over 20 min, \u03bb = 214 nm; <sup>i</sup>20-30%, <sup>ii</sup>23-33%, <sup>iii</sup>25-35% <sup>c</sup>Competitive cyclin A binding assay using immobilised biotinyl-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub></p>Example 25 Peptide Analogues of H-Ala-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>MS<sup>a</sup>RP-HPLC<sup>b</sup>[M +PurityCompoundFormulaM<sub>r</sub>H]<sup>+</sup>t<sub>R </sub>(min)(%)H-Ala-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>45</sub>H<sub>79</sub>FN<sub>16</sub>O<sub>8</sub>991.2991.112.4590H-Gly-Ala-Lys-Arg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>44</sub>H<sub>77</sub>FN<sub>16</sub>O<sub>8</sub>977.2976.415.994H-Ala-Ala-Lys-hArg-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>46</sub>H<sub>81</sub>FN<sub>16</sub>O<sub>8</sub>1005.31004.112.4785H-Ala-Ala-Lys-Ser-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>42</sub>H<sub>72</sub>FN<sub>13</sub>O<sub>9</sub>922.1921.012.6487H-Ala-Ala-Lys-Hse-Arg-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>43</sub>H<sub>74</sub>FN<sub>13</sub>O<sub>9</sub>936.1935.512.6887H-Ala-Ala-Lys-Arg-Lys-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>45</sub>H<sub>79</sub>FN<sub>14</sub>O<sub>8</sub>963.2962.312.2490H-Ala-Ala-Lys-Arg-Orn-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>44</sub>H<sub>77</sub>FN<sub>14</sub>O<sub>8</sub>949.2948.312.3595H-Ala-Ala-Lys-Arg-Gln-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>44</sub>H<sub>75</sub>FN<sub>14</sub>O<sub>9</sub>963.2962.612.5893H-Ala-Ala-Lys-Arg-Hse-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>43</sub>H<sub>74</sub>FN<sub>13</sub>O<sub>9</sub>936.1934.912.8390H-Ala-Ala-Lys-Arg-Thr-Leu-Ile-pFPhe-NH<sub>2</sub>C<sub>43</sub>H<sub>74</sub>FN<sub>13</sub>O<sub>9</sub>9",
    "sub>27</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>Cl611.1611.3VI.27C<sub>30</sub>H<sub>50</sub>N<sub>11</sub>O<sub>5</sub>Cl680.2680.5VI.28C<sub>27</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>Cl611.1611.4VI.29C<sub>30</sub>H<sub>50</sub>N<sub>11</sub>O<sub>5</sub>Cl680.2680.4VI.30C<sub>28</sub>H<sub>49</sub>N<sub>11</sub>O<sub>5</sub>S651.8652.5VI.31C<sub>25</sub>H<sub>41</sub>N<sub>8</sub>O<sub>5</sub>F552.6553.0VI.32C<sub>28</sub>H<sub>48</sub>N<sub>11</sub>O<sub>4</sub>F621.8622.0VI.33C<sub>28</sub>H<sub>48</sub>N<sub>11</sub>O<sub>4</sub>F621.8622.9VI.34C<sub>28</sub>H<sub>48</sub>N<sub>11</sub>O<sub>4</sub>Cl638.2638.5VI.35C<sub>28</sub>H<sub>48</sub>N<sub>11</sub>O<sub>4</sub>Cl638.2638.5VI.36C<sub>26</sub>H<sub>47</sub>N<sub>11</sub>O<sub>4</sub>S609.8610.5VI.37C<sub>25</sub>H<sub>41</sub>N<sub>8</sub>O<sub>5</sub>Cl569.1569.5VI.38C<sub>30</sub>H<sub>51</sub>N<sub>11</sub>O<sub>5</sub>645.8649.2VI.39C<sub>27</sub>H<sub>44</sub>N<sub>8</sub>O<sub>6</sub>576.7580.6VI.40C<sub>31</sub>H<sub>53</sub>N<sub>11</sub>O<sub>5</sub>659.8674.6VI.41C<sub>28</sub>H<sub>46</sub>N<sub>8</sub>O<sub>6</sub>590.7590.5VI.42C<sub>21</sub>H<sub>30</sub>N<sub>5</sub>O<sub>5</sub>F451.5452.2VI.43C<sub>28</sub>H<sub>48</sub>N<sub>11</sub>O<sub>5</sub>F637.8638.2VI.44C<sub>28</sub>H<sub>46</sub>N<sub>9</sub>O<sub>7</sub>F639.7640.2VI.45C<sub>31</sub>H<sub>49</sub>N<sub>9</sub>O<sub>6</sub>643.8646.0</p>Example 30 Biological Activity of Compounds of Formula VI (Defined in Ex. 28) Competitive Binding Assay  This assay was performed using half-area black 96-well microtitre plates. To each well were added: 10 \u03bcL assay buffer (25 mM HEPES pH 7, 10 mM NaCl, 0.01% Nonidet P-40, 1 mM dithiothreitol), 10 \u03bcL test compound solution (in 10% aq DMSO), 10 \u03bcL CDK2/cyclin A (ca. 2 \u03bcg purified recombinant human kinase complex) in assay buffer, and 10 \u03bcL tracer peptide solution (150 nM fluorescein-Ahx-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-NH<sub>2</sub>; refer McInnes, C. et al., 2003, Curr. Med. Chem. Anti-Cancer Agents, 3, 57; Atkinson, G. E. et al., 2002, Bioorg. Med. Chem. Lett., 12, 2501) in assay buffer. After incubation with shaking for 1 h at room temperature, fluorescence polarisation at 485-520 nm was measured using a Tecan Ultra reader. Half-maximal inhibition (IC<sub>50</sub>) was calculated from dose\u2014response curves. </p> Functional Kinase Assay </p> CDK2/cyclin A kinase assays (phosphorylation of natural retinoblastoma protein (pRb)) were performed in 96-well plates using recombinant proteins. To each well were added: 10 \u03bcL assay buffer (50 mM HEPES pH 7.4, 20 mM \u03b2-glycerophosphate, 5 mM EGTA, 2 mM dithiothreitol, 1 mM NaVO<sub>3</sub>, and 20 mM MgCl<sub>2</sub>), 5 \u03bcL GST-pRb(773-928) substrate stock solution, 10 \u03bcL test compound solution, 10 \u03bcL (2-5 \u03bcg protein) of purified recombinant human CDK2/cyclin A stock. The reaction was initiated by addition of 10 \u03bcL/well Mg/ATP mix (15 mM MgCl<sub>2</sub>, 100 \u03bcM ATP with 30-50 kBq per well of [\u03b3-<sup>32</sup>P]-ATP) and mixtu"
]